Related references
Note: Only part of the references are listed.Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease
Solene Querellou et al.
ANNALS OF HEMATOLOGY (2006)
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients:: when do we really need FDG-PET?
MJ Reinhardt et al.
ANNALS OF ONCOLOGY (2005)
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
NG Mikhaeel et al.
ANNALS OF ONCOLOGY (2005)
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma:: an early prognostic tool for predicting patient outcome
C Haioun et al.
BLOOD (2005)
Response assessment of aggressive non-Hodgkin's lymphoma by integrated international workshop criteria and fluorine-18-fluorodeoxyglucose positron emission tomography
ME Juweid et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
[18F]FDG PET monitoring of tumour response to chemotherapy:: does [18F]FDG uptake correlate with the viable tumour cell fraction?
K Spaepen et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Accuracy of whole-body F-18-FDP-PET for restaging malignant lymphoma
P Mikosch et al.
ACTA MEDICA AUSTRIACA (2003)
Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
K Spaepen et al.
ANNALS OF ONCOLOGY (2002)
18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT
NG Mikhaeel et al.
LEUKEMIA & LYMPHOMA (2000)
Share Paper
